First Time Loading...

Cardiex Ltd
ASX:CDX

Watchlist Manager
Cardiex Ltd Logo
Cardiex Ltd
ASX:CDX
Watchlist
Price: 0.076 AUD Market Closed
Updated: Mar 29, 2024

Intrinsic Value

CDX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

CardieX Ltd. is engaged in the designing, manufacturing, and marketing of medical devices for use in cardiovascular health management. [ Read More ]

The intrinsic value of one CDX stock under the Base Case scenario is 0.306 AUD. Compared to the current market price of 0.076 AUD, Cardiex Ltd is Undervalued by 75%.

Key Points:
CDX Intrinsic Value
Base Case
0.306 AUD
Undervaluation 75%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Cardiex Ltd

Backtest CDX Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CDX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Cardiex Ltd

Current Assets 14.5m
Cash & Short-Term Investments 4.3m
Receivables 1.6m
Other Current Assets 8.6m
Non-Current Assets 2.3m
Long-Term Investments 369.7k
PP&E 1.3m
Intangibles 625.5k
Other Non-Current Assets 42.2k
Current Liabilities 14.2m
Accounts Payable 7.4m
Accrued Liabilities 502.1k
Short-Term Debt 1.5m
Other Current Liabilities 4.8m
Non-Current Liabilities 2.6m
Long-Term Debt 2.6m
Other Non-Current Liabilities 9.5k
Efficiency

Earnings Waterfall
Cardiex Ltd

Revenue
12.9m AUD
Cost of Revenue
-916k AUD
Gross Profit
12m AUD
Operating Expenses
-16.7m AUD
Operating Income
-4.7m AUD
Other Expenses
-4.7m AUD
Net Income
-9.4m AUD

Free Cash Flow Analysis
Cardiex Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

CDX Profitability Score
Profitability Due Diligence

Cardiex Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
Declining ROE
25/100
Profitability
Score

Cardiex Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

CDX Solvency Score
Solvency Due Diligence

Cardiex Ltd's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Short-Term Solvency
Long-Term Solvency
High D/E
35/100
Solvency
Score

Cardiex Ltd's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CDX Price Targets Summary
Cardiex Ltd

There are no price targets for CDX.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

CDX Price
Cardiex Ltd

1M 1M
-3%
6M 6M
-44%
1Y 1Y
-68%
3Y 3Y
-89%
5Y 5Y
-80%
10Y 10Y
-93%
Annual Price Range
0.076
52w Low
0.076
52w High
0.37
Price Metrics
Average Annual Return 15.74%
Standard Deviation of Annual Returns 77.53%
Max Drawdown -93%
Shares Statistics
Market Capitalization 14.7m AUD
Shares Outstanding 193 747 000
Percentage of Shares Shorted
N/A

CDX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Cardiex Ltd Logo
Cardiex Ltd

Country

Australia

Industry

Health Care

Market Cap

14.7m AUD

Dividend Yield

0%

Description

CardieX Ltd. is engaged in the designing, manufacturing, and marketing of medical devices for use in cardiovascular health management. The company is headquartered in Sydney, New South Wales. The company went IPO on 2005-11-09. The firm is focused on designing, manufacturing and marketing medical devices for use in cardiovascular health management. The company operates through its subsidiaries, including ATCOR and CONNEQT. The firm's ATCOR division provides medical devices for measuring arterial stiffness and central blood pressure waveforms based on its FDA-cleared and patented SphygmoCor technology. Under the ATCOR.X brand, the Company also develops and licenses its Arty platform consisting of physiological and health analytics for wearable devices. The firm's digital platform, ArtyNet, is a connected software as a service ecosystem providing physicians with a telehealth solution for remotely managing patients' health. CONNEQT develops and markets consumer wearable and home health devices focused on heart health and its patented fitness and wellness parameters.

Contact

NEW SOUTH WALES
Sydney
Suite 303, 15 Lime Street
+61298748761.0
https://cardiex.com/

IPO

2005-11-09

Employees

-

Officers

Co-Founder & Executive Chairman
Mr. Niall Charles Edgar Cairns ACA, B.Ec, FAICD
Co-Founder, Group CEO, MD & Executive Director
Mr. Craig R. Cooper BEC, L.L.B.
Chief Science & Research Officer
Dr. Ahmad Qasem Ph.D.
Chief Medical Officer
Dr. Steven Kesten
Chief Product Officer
Dr. Mark Gorelick Ph.D.
Chief Strategy Officer
Ms. Catherine Liao
Show More
President of CONNEQT
Mr. Josh Stevens
Global Head of Marketing & Communications
Mr. Antony Sloan
Executive VP & Head of Global Sales for AtCor Medical Division
Mr. Douglas T. Kurschinski
Company Secretary
Ms. Louisa Ho
Show Less

See Also

Discover More
What is the Intrinsic Value of one CDX stock?

The intrinsic value of one CDX stock under the Base Case scenario is 0.306 AUD.

Is CDX stock undervalued or overvalued?

Compared to the current market price of 0.076 AUD, Cardiex Ltd is Undervalued by 75%.